Pfizer Inc
NYSE:PFE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.59
27.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.8B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
954.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547B USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
268.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.9B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
265.9B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.4B EUR |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
84.1B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Pfizer Inc
Glance View
Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Pfizer Inc is 29.1%, which is above its 3-year median of 28.3%.
Over the last 3 years, Pfizer Inc’s Operating Margin has decreased from 39.9% to 29.1%. During this period, it reached a low of 19.4% on Mar 31, 2024 and a high of 40.3% on Dec 31, 2022.